sdAb as Therapeutic Agent

Full-length monoclonal antibodies have been highly successful as therapeutic agents against various immune diseases and cancers. However, the large size severely limits their applications. As an alternative, single domain antibodies (sdAbs) present great advantages as novel therapeutic agents, such as small size, high expression, improved robustness, and a large number of accessible epitopes. Creative Biolabs is committed to providing customized proposals and solutions to develop novel sdAb-based therapeutics for disease treatment.

We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.